Publications by authors named "Weilang Li"
Article Synopsis
- COVID-19, caused by SARS-CoV-2, can lead to a range of symptoms from none to severe, with immune responses demonstrating decreased T- and B-cell counts early on, and detectable antibodies appearing within 14 days after symptoms start.
- COVID-19-convalescent individuals show variable levels of spike-specific neutralizing antibodies; severe cases had higher antibody levels and better immune responses compared to those with milder disease.
- The study indicates that neutralizing antibodies can cross-react with other coronaviruses and highlights the importance of these responses for future treatment and vaccine strategies.
Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke but poses risk for hemorrhagic transformation (HT). Cell therapy has been investigated as a potential therapy to improve recovery after stroke by the modulation of inflammatory responses and the improvement of blood-brain barrier (BBB) integrity, both of which are associated with HT after t-PA. In our present study, we studied the effect of autologous bone marrow mononuclear cells (MNCs) in an embolic stroke model.
View Article and Find Full Text PDFParkinson's disease (PD) is the second most common progressive neurodegenerative movement disorder. Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the first rate‑limiting step in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway in mammals, is a substrate for NAD+‑dependent enzymes, such as sirtuin 1 (SIRT1), and contributes to cell fate decisions. However, the role of NAMPT in PD has remained to be fully elucidated.
View Article and Find Full Text PDF